Diabetic Gastroparesis Study 05

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS

Intervention/treatment:
RELAMORELIN
Medical condition:
DIABETIC GASTROPARESIS
Protocol code:
3071-305-020
Control number:
229221
Status:
Closed
Approved:
July 24, 2019
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03786380
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Therapeutic Area, Head
Organization
Allergan
Phone:
714-246-4500
Sponsor
ALLERGAN INC

Locations

Alberta

Alberta Diabetes Institute
Edmonton, Alberta, T6G 2E1
University of Calgary
Calgary, Alberta, T2N 4Z6

British Columbia

Vancouver General Hospital
Vancouver, British Columbia, V5Z1M9

Newfoundland and Labrador

Central Alberta Research Centre
Red Deer, Newfoundland and Labrador, T4N 6V7
Eastern Health
St. John's, Newfoundland and Labrador, NL A1B 3V6

Nova Scotia

South Shore Medical Arts
Bridgewater, Nova Scotia, B4V 2V6

Ontario

Dr. Anil K. Gupta Medicine Professional Corporation
Etobicoke, Ontario, M9V4B4
Sunnybrook Health Science Centre
Toronto, Ontario, M4N 3M5
The Ottawa Hospital
Ottawa, Ontario, K1H 7W9
Toronto Digestive Disease Associates
Vaughan, Ontario, L4L 4YZ
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
Toronto Western Hospital, University Health Network
Toronto, Ontario, M5T 2S8

Quebec

Centre Hospitalier de l'Universite de Montreal - CHUM
Montreal, Quebec, H2X 0A9
CISSS de la Monteregie-Centre
Greenfield Park, Quebec, J4V 2H1
Recherche GCP Research
Montreal, Quebec, H1M 1B1

Results

See the results from the trial NCT03786380. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?